LEXINGTON, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent
Trials and Appeal Board (PTAB) of the U.S. Patent and Trademark Office
has denied Incyte's petition to institute inter partes review (IPR) of
U.S. Patent No. 9,249,149 (the ‘149 patent). The denial of Incyte's IPR
petition upholds the validity of the ‘149 patent that includes claims
covering CTP-543, the Company's investigational compound for the
treatment of alopecia areata.
"We are very pleased that the PTAB did not institute the IPR, and that
our composition-of-matter patent relating to CTP-543 remains valid and
enforceable," stated Roger Tung, President and Chief Executive Officer
of Concert Pharmaceuticals. "This is the second case in which the PTAB
has elected not to institute an IPR challenge to a deuterated compound
based on a pre-existing drug and further supports Concert's technology
In April 2017, Incyte filed a petition challenging the validity of the
‘149 patent. Documents relating to the IPR can be accessed online at: http://www.concertpharma.com/technology-overview/intellectual-property/
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to address unmet patient needs. The Company's
approach starts with approved drugs in which deuterium substitution has
the potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad
pipeline of innovative medicines targeting autoimmune and
inflammatory diseases and central nervous systems (CNS) disorders. For
more information please visit www.concertpharma.com.
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about the strength of
Concert's intellectual property, and other statements containing the
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict," "project,"
"should," "target," "would," and similar expressions, constitute
forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including factors discussed in the "Risk
Factors" section of our most recent Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission and in other filings that we
make with the Securities and Exchange Commission. In addition, any
forward-looking statements included in this press release represent our
views only as of the date of this release and should not be relied upon
as representing our views as of any subsequent date. We specifically
disclaim any obligation to update any forward-looking statements
included in this press release.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171019006221/en/
Concert Pharmaceuticals, Inc.
Kathryn Morris, 845-635-9828
Source: Concert Pharmaceuticals, Inc.
News Provided by Acquire Media